CS270542B1 - Mouse lymphocyte hybridoma vu cf2 - Google Patents
Mouse lymphocyte hybridoma vu cf2 Download PDFInfo
- Publication number
- CS270542B1 CS270542B1 CS888953A CS895388A CS270542B1 CS 270542 B1 CS270542 B1 CS 270542B1 CS 888953 A CS888953 A CS 888953A CS 895388 A CS895388 A CS 895388A CS 270542 B1 CS270542 B1 CS 270542B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- hybridoma
- influenza
- virus
- mouse
- antibody
- Prior art date
Links
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Riešerjie sa týká myšieho lymfocytárneho hybridómu, produkujúceho protilátku κ podtriedy IgG 1 proti lehkému retezcu t. hemeglutínlnu virusu chřipky A. Hybridóm je uložený v zbierke hybridomov Virologickóho ústavu SAV v Bratislavě pod ozne- * čenlm VU CF2.Riešerjie refers to mouse lymphocytic antibody-producing hybridoma κ IgG 1 subclass against light chain t. influenza hemegglutinin virus A. Hybridoma is stored in the Virologic's hybridoma collection Institute of SAS in Bratislava * VU CF2.
Description
Vynález ea týká myšieho lymfocytárneho hybridómu, tj. hybridného jadnobunkového organizmu, zostrojsného buňkovou fúziou myšej myelomovej linie Sp2/0 a myšej slezinovej buňky, produkujúceho protilátky proti Xahkému retazcu (HA ) hemaglutininu virusu chřipky A subtypu H3.The invention relates to a murine lymphocyte hybridoma, i. a hybrid nuclear cell organism constructed by a cell fusion of a mouse myeloma line Sp2 / 0 and a mouse spleen cell producing antibodies against the light chain (HA) of hemagglutinin influenza A virus subtype H3.
Protilátky voči protslnom virusu chřipky sa doteraz pripravujú tak, že virus resp. jeho izolované proteiny sa opakované injikujú ako antigén pokusným zvieratám, najčastejiie králikom, myšiam, alebo fretkám. Sérum takto imunizovaných zvierat, ódobraté po určité j době posobenia antigénu, slúži ako zdroj protilátek, používaných predovšetkým pre kvantitativnu alebo kvalitatlvnu analýzu antigénu - virusu chřipky - vo výzkume a v imunodiagnostickej praxi.Antibodies to influenza virus are hitherto prepared in such a way that the virus resp. its isolated proteins are repeatedly injected as an antigen into experimental animals, most often rabbits, mice, or ferrets. Serum from such immunized animals, collected after a certain period of antigen exposure, serves as a source of antibodies, used primarily for quantitative or qualitative analysis of the antigen - influenza virus - in research and immunodiagnostic practice.
Tento postup, nazývaný konvenčnou imunizáciou, má niekolko nevýhod. V sére imunizovaných zvierat sa nachádza heterogénna zmes protilátek, kterých spektrum je v každom Jednotlivom organizme rožne a neopakovatelné. Organizmus spravidla vytvoří okrem protilátok voči žiadanému antigénu i protilátky voči nečistotám antigénového preparátu, ktoré je potřebné zo, sér odstraňovat vysycovaním. Výrobné Šarže konvenčných sér sa preto dajú tažko Standardizovat a bývajú v širokom rozmedzí kvality. Pře výrobu každej šarže třeba připravit čistý imunizačný antigén a clalšie antigény na vysýtenie balastných protilátek proti nečistotám.This procedure, called conventional immunization, has several disadvantages. The serum of immunized animals contains a heterogeneous mixture of antibodies, the spectrum of which is spicy and unrepeatable in each individual organism. As a rule, in addition to antibodies to the desired antigen, the organism also produces antibodies to impurities of the antigen preparation which need to be removed from the sera by saturation. Production batches of conventional sera are therefore difficult to standardize and tend to be in a wide range of quality. For the production of each batch, pure immunizing antigen and other antigens must be prepared to saturate the ballast antibodies against impurities.
Uvedené nedostatky vyššie zelenaného a doslal používaného postupu sa odstránia, ak je k dispozicii hybridóm, produkujúci monoklonálnu protilátku proti Xahkému retazcu hemaglutininu virusu chřipky A subtypu H3, uložený v zbierke hybridómov Virologického ústavu SAV v Bratislavě, Mlýnská dolina 1, pod označením VU CF2.The above-mentioned shortcomings of the above-green and obtained procedure are eliminated if a hybridoma producing a monoclonal antibody against the X-chain hemagglutinin of influenza A virus subtype H3, stored in the hybridoma collection of the Institute of Virology in Bratislava, Mlýnská dolina 1, under the designation VU CF2, is available.
Uvedený hybridóm bol získaný sposobom známým z odbornej literatúry ^Kohler. G., Milstein. C.: Continuous cultures of fused cello secreting antibody of predefined specificity. Nature 256. (1975Ú, 496: Gerhard. W.: Fusion of cells in suspension and outgrowth of hybrids in conditioned medium. In: Monoclonal antibodies. Hybrids: A New Dimension in Biological Analyses, R. H. Ksnnet, T. 3. McKeam, K. B. Bschtol, eds., New York, Plenum Press (1980), 370.) klonováním súboru hybridných buniek po fúzii myšej myelómovéj linie Sp2/0 a buniek, získaných zo áleziny myší kmeňa BALB/c, imunizovaných Xahkýa retazcom hemaglutininu (HA )'virusu chřipky A/Dunedin/4/73 (H3N2).Said hybridoma was obtained by a method known from the Kohler literature. G., Milstein. C .: Continuous cultures of fused cello secreting antibody of predefined specificity. Nature 256. (1975Ú, 496: Gerhard. W .: Fusion of cells in suspension and outgrowth of hybrids in conditioned medium. In: Monoclonal antibodies. Hybrids: A New Dimension in Biological Analyzes, RH Ksnnet, T. 3. McKeam, KB Bschtol, eds. influenza A / Dunedin / 4/73 (H3N2).
Výhodou hybridómu podXa vynálezu je, že produkuje homogénnu protilátku, tzv. monoklonálnu protilátku, ktorá je schopná Specificky reagovat s homaglutininom chřipkového virusu typu A subtypu H3. Hybridou VU CF2 možno kultivovat in vitro v médiách vhodných prs živočišná buňky, alebo in vivo v paritoneálnej dutina myši kmeňa BALB/c. Z konzerv, uchovaných v kvapalnom dusíku, možno zahájit produkciu protilátky bez ďalšej imunizácie antigénom.The advantage of the hybridoma according to the invention is that it produces a homogeneous antibody, the so-called a monoclonal antibody that is capable of specifically reacting with homagglutinin of influenza A virus of subtype H3. The VU CF2 hybrid can be cultured in vitro in media suitable for animal cells, or in vivo in the paritoneal cavity of a BALB / c mouse. From cans stored in liquid nitrogen, antibody production can be initiated without further immunization with antigen.
PřikladExample
Pra účel pomnoženia hybrldómových buniek in vivo sa aplikovalo 5xl04 buniek do peritoneálnej dutiny myši. Pre lepšie uchytenie aplikovaných buniek bola myš 15 dní před přenosem buniek hybridómu premedikovaná parafinovým olejom (0,5 ml intraperitoneálne). Po 20 dňoch rastu hybridómu v peritoneálnej dutině bola myš zabitá a vyprodukovaná ascitická tekutina odobratá. Celkom sa získalo 7 ml ascitickej tekutiny obsahujúcej 7 mg/ml imunoglobulinu. Ascitická tekutina, obsahujúca produkt hybridómu VU CF2, vykazovala špacifickú vazbu k virusem chřipky typu A subtypu H3, ale nie voči iným subtypom, k izolovanému hemaglutininu subtypu H3 a k izolovanému Xahkému retazcu (HA ) hemaglutininu subtypu H3 v radioimunologickom teste. Viazala sa na lehký retazec (HA ) hemaglutininu v radioimunoprecipitačnom teste.To multiply hybridoma cells in vivo, 5x10 4 cells were applied to the peritoneal cavity of the mouse. To better adhere the applied cells, the mouse was premedicated with paraffin oil (0.5 ml intraperitoneally) 15 days before transferring the hybridoma cells. After 20 days of growth of the hybridoma in the peritoneal cavity, the mouse was sacrificed and the ascitic fluid produced was collected. A total of 7 ml of ascitic fluid containing 7 mg / ml immunoglobulin was obtained. The ascitic fluid containing the VU CF2 hybridoma product showed specific binding to influenza A virus of subtype H3, but not to other subtypes, to isolated hemagglutinin of subtype H3 and to isolated X-chain (HA) hemagglutinin of subtype H3 in a radioimmunoassay. It bound to the light chain (HA) of hemagglutinin in a radioimmunoprecipitation assay.
In vitro rastů buňky hybridómu ako polosuspsnzná kultúra. Majů tvar (gul'atý) a veřIn vitro hybridoma cell growth as a semi-succulent culture. May's shape (gul'atý) and ver
CS 270 542 Bl kost charakteristické pre myelómové buňky, obsahujú fúzované buňkové jadrá, eú aneuploidné. Buňky hybridómu VU CF 2 majú ultraštruktúrny obraz typických myelómových buniek, kde prevažujúcou organelou eú volné a na membrány viazané polyribozómy. Základným kultivačným médiom je Oulbeccova modifikécia Eaglovho minimálneho eeenciálneho média (Dulbecco, R. a Freeman. G., Virology 8 (1959), 396). Toto médium, označované ako DMEM, je pre kultiváciu hybridómu doplněné gentamycínom a inaktivovaným prekoloetrálnym eérom (10%, Bioveta, Ivanovice na Hané). Hybridóm je kultivovaný pri 37 °C - jeho středná generačná doba je přibližné 24 h. Produkovaná protilátka je monoklonálny imunoglobulin podtriedy igGl.CS 270 542 Bacteria characteristic of myeloma cells, contain fused cell nuclei, eu aneuploid. VU CF 2 hybridoma cells have an ultrastructural image of typical myeloma cells, where the predominant organelle eu are free and membrane-bound polyribosomes. The basic culture medium is Oulbecco's modification of Eagle's minimal essential medium (Dulbecco, R. and Freeman. G., Virology 8 (1959), 396). This medium, designated DMEM, is supplemented with gentamicin and inactivated precolethral er (10%, Bioveta, Ivanovice na Hané) for hybridoma culture. The hybridoma is cultured at 37 ° C - its mean generation time is approximately 24 hours. The antibody produced is a monoclonal immunoglobulin of the igG1 subclass.
Hybridóm VU CF 2 ea mGže priemyeelne využívat ako zdroj protilátky proti hemaglutinínu virusu chřipky A subtypu H3 v metodách analytických, preparativnych alebo diagnostických a to:The VU CF 2 ea hybridoma can be used industrially as a source of antibody against hemagglutinin of influenza A virus subtype H3 in analytical, preparative or diagnostic methods, namely:
X 1) pri kvantitativném a kvalitatívnom vyhodnocovaní přítomnosti hemaglutininu virusu chřipky A subtypu H3 vo vyšetrovanom materiál! (napr. klinické vzorky).X 1) in the quantitative and qualitative evaluation of the presence of influenza A virus subtype H3 haemagglutinin in the investigated material! (eg clinical specimens).
, 2) pri vyhodnocovaní epidemiologickej eituácie,, 2) in the evaluation of the epidemiological evaluation,
3) pri purifikácii hemaglutininu vírueu chřipky A eubtypu H3,3) in the purification of H3 influenza A eubtype haemagglutinin,
4) ako zdroj protilátky jedinej podtriedy (IgG 1) pre přípravu eér specifických pre uvedené podtriedu.4) as a source of a single subclass antibody (IgG 1) for the preparation of eros specific for said subclass.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS888953A CS270542B1 (en) | 1988-12-29 | 1988-12-29 | Mouse lymphocyte hybridoma vu cf2 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CS888953A CS270542B1 (en) | 1988-12-29 | 1988-12-29 | Mouse lymphocyte hybridoma vu cf2 |
Publications (2)
Publication Number | Publication Date |
---|---|
CS895388A1 CS895388A1 (en) | 1989-11-14 |
CS270542B1 true CS270542B1 (en) | 1990-07-12 |
Family
ID=5440809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CS888953A CS270542B1 (en) | 1988-12-29 | 1988-12-29 | Mouse lymphocyte hybridoma vu cf2 |
Country Status (1)
Country | Link |
---|---|
CS (1) | CS270542B1 (en) |
-
1988
- 1988-12-29 CS CS888953A patent/CS270542B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CS895388A1 (en) | 1989-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brown et al. | Indirect 125I-labeled protein A assay for monoclonal antibodies to cell surface antigens | |
JPS59180362A (en) | Use of anti-idiotype antibody in immune determination method | |
RU2366663C2 (en) | Immunoassay device with using influenza b virus antibody | |
GB2144147A (en) | Monoclonal antibody having only one light chain which will bind a specific antigen | |
CS270542B1 (en) | Mouse lymphocyte hybridoma vu cf2 | |
KR880005258A (en) | Monoclonal antibodies against IFN-Omega, methods for their preparation, and their use for the purification and detection of IFN-Omega | |
CS270543B1 (en) | Mouse lymphocyte hybridoma vu 2-l/5 | |
CS270544B1 (en) | Mouse lymphocyte hybridoma vu iih3 | |
CS269049B1 (en) | Mouse lymphocytar hybridome vu 315/4 | |
JP2009508087A (en) | Monoclonal antibody reagent | |
CS269050B1 (en) | Mouse lymphocytar hybridome vu vih7 | |
CS267393B1 (en) | Mouse lymphocytar hybridoma vu ifn b13 | |
CS267391B1 (en) | Mouse lymphocytar hybridoma vu ifn g8 | |
CS267392B1 (en) | Mouse lymphocytar hybridom vu ifn al 6 | |
CS267394B1 (en) | Mouse lymphocytar hybridoma vu ifn bba6 | |
CS240846B1 (en) | Mouse lymphatic hybridom img czas in-%4 | |
CS270537B1 (en) | Mouse lymphocyte hybridoma vu 144/1-2 | |
RU2093572C1 (en) | Strain of hybrid cultured cells mus musculus l used for preparing monoclonal antibody raised to l-chains of immunoglobulins | |
JP2021081317A (en) | Measuring method using anti-immunocomplex antibody | |
CS234935B1 (en) | Mousy lymphocytoid hybrid img ozas b2m-01 | |
CS240807B1 (en) | Mouse lymphatic hybridom imb czas tec-%1 | |
CS263122B1 (en) | Mouse lymphocytaric hybridom producing antibody against human alpha-fetoproteine | |
CS233810B1 (en) | Mousy lymphocytoid hybride generating antimatter against piggish and human insulin | |
CS222781B1 (en) | Electromotor with friction brake with decreased noise | |
CS243348B1 (en) | Mousy lymphocytoid hybridom img-czas hft-21 |